Type II Diabetes Mellitus
Conditions
Brief summary
Primary Objective: To evaluate the ability of lixisenatide to modulate postprandial hyperlipidemia in particular, the effects on plasma changes in triglycerides. Secondary Objectives: The effect of lixisenatide on the following postprandial lipids: apolipoprotein (APO) B48; free fatty acid, lipoprotein distribution, cholesterol, and low-density lipoprotein (LDL) oxidation. The effect of lixisenatide on chronic low-grade inflammation present in non-insulin dependent diabetes mellitus (NIDDM) and obesity. The effect of lixisenatide on microvascular dysfunction. To evaluate the effect of lixisenatide on postprandial plasma glucose, insulin and C-peptide and glucagon.
Detailed description
Maximum study duration of approximately 2.5 months (study treatment) ± 2 days Day 0 (baseline) plus a 10-week open-label, active-controlled treatment period (Final/End-of-treatment Visit).
Interventions
Pharmaceutical form:solution Route of administration: subcutaneous
DRUGmetformin
Pharmaceutical form:tablet Route of administration: oral
Sponsors
Sanofi
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Male and female patients, 18-70 years of age. Diagnosis of Type 2 diabetes treated with metformin and obesity (body mass index \[BMI\] \>30 kg/m\^2) and the following other abnormalities: * Abdominal obesity (waist circumference \>102 cm in men and \>88 cm in women). According to National Cholesterol Education Program-Adult Treatment Panel (NCEP-ATP) III (2001). * Glycated hemoglobin A1c (HbA1c) ≥7 and ≤8.5% (after Sponsor approval providers might reasonably suggest more stringent A1c goals \[such as 6.5%\] for selected individual patients, if this can be achieved without significant hypoglycemia or other adverse effects of treatment. Appropriate patients might include those with short duration of diabetes, long life expectancy, and no significant cardiovascular disease). * Hypertriglyceridemia (fasting triglyceride levels between 150 mg/dL and 600 mg/dL, cholesterol \<300 mg/dL. In order to exclude patients who might be suffering from a primitive dyslipidemia). * Low high-density lipoprotein (HDL) cholesterol (serum HDL-cholesterol \<40 mg/dL in men and \<50 mg/dL in women). Written informed consent.
Exclusion criteria
Smoking. Thyroid disease even if under appropriate hormonal replacement therapy or thyroid suppressant (Thyroid Stimulating Hormone \[TSH\] \>5 mU/L with clinical symptoms of hypothyroidism). Hepatic disease (Aspartate Aminotransferase \[ASAT\] or Alanine Aminotransferase \[ALAT\] \>2 times the upper limit of normal). Renal disease (serum creatinine \>1.7 times the upper limit of normal). A history of coronary heart disease, cerebrovascular disease, or peripheral arterial disease in the 6 months before enrollment. History of malignancies. Use of lipid lowering therapy. Systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg. Triglycerides \>600 mg/dL. History of chronic pancreatitis or of idiopathic acute pancreatitis. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min) | After 10 weeks of treatment |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in plasma cholesterol | 2 days after the basal test and after 10 weeks of treatment |
| Change from baseline in APO B48 | 2 days after the basal test and after 10 weeks of treatment |
| Change from baseline in free fatty acid levels | 2 days after the basal test and after 10 weeks of treatment |
| Change from baseline in lipoprotein distribution | 2 days after the basal test and after 10 weeks of treatment |
| Change from baseline in LDL oxidation | 2 days after the basal test and after 10 weeks of treatment |
| Change from baseline in plasma triglyceride | 2 days after the basal test and after 10 weeks of treatment |
| Change from baseline in insulin | 2 days after the basal test and after 10 weeks of treatment |
| Change from baseline in C-peptide | 2 days after the basal test and after 10 weeks of treatment |
| Change from baseline in low grade inflammation (cytokines and stress oxidative markers) | 2 days after the basal test and after 10 weeks of treatment |
| Change in baseline coronary flow reserve to assess the effect of lixisenatide on microvascular dysfunction | 2 days after the basal test and after 10 weeks of treatment |
| Change from baseline in postprandial plasma glucose | 2 days after the basal test and after 10 weeks of treatment |
Outcome results
None listed